翻訳と辞書 |
ADB-CHMINACA : ウィキペディア英語版 | ADB-CHMINACA
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication.〔(【引用サイトリンク】 title=MAB-CHMINACA )〕 It was identified in cannabinoid blends in Japan in early 2015. == Side Effects ==
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「ADB-CHMINACA」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|